Abbott Narrowed Its Full-year 2024 Organic Sales Growth Guidance Range, Excluding Covid-19 Testing-related Sales, To 9.5% To 10.0% Versus Prior Rage Of 8.5%-10.0%
Portfolio Pulse from Benzinga Newsdesk
Abbott Laboratories has adjusted its full-year 2024 organic sales growth guidance range, excluding Covid-19 testing-related sales, to 9.5% to 10.0%, up from the previous range of 8.5% to 10.0%.
July 18, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott Laboratories has revised its full-year 2024 organic sales growth guidance to 9.5%-10.0%, excluding Covid-19 testing-related sales, from the previous range of 8.5%-10.0%. This indicates a more optimistic outlook for the company's core business.
The upward revision in sales growth guidance suggests that Abbott's core business is performing better than previously expected. This positive outlook is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100